Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adamas Pharma 1900 POWELL ST. SUITE 1000 EMERYVILLE CA 94608 USA

P: 510-450-3500 F: 510-428-0519

Description:

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.

Key Statistics

Overview:

Market Capitalization, $K 77,716
Shares Outstanding, K 28,158
Annual Sales, $ 54,640 K
Annual Net Income, $ -105,190 K
Last Quarter Sales, $ 14,480 K
Last Quarter Net Income, $ -16,650 K
60-Month Beta 1.76
% of Insider Shareholders 24.90%
% of Institutional Shareholders 55.33%
Float, K 21,147
% Float 75.10%

Growth:

1-Year Return -42.14%
3-Year Return -83.65%
5-Year Return -85.74%
5-Year Revenue Growth -2.17%
5-Year Earnings Growth -816.98%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/07/20
Earnings Per Share ttm -3.31
EPS Growth vs. Prev Qtr 28.92%
EPS Growth vs. Prev Year 45.37%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ADMS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -3.72
Price/Earnings to Growth N/A
Return-on-Equity % -806.55%
Return-on-Assets % -53.66%
Profit Margin % -192.51
Net Margin % N/A
Debt/Equity N/A
Price/Sales 1.42
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.56
Interest Coverage -5.99
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar